Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterisation of Dengue Vaccine (Qdenga®, TAK-003)-Induced Humoral and Cellular Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination

NCT06776692 is registered in ClinicalTrials.gov with IRCCS Sacro Cuore Don Calabria di Negrar as lead sponsor.

NCT NCT06776692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06776692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterisation of Dengue Vaccine (Qdenga®, TAK-003)-Induced Humoral and Cellular Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination
Lead sponsor
IRCCS Sacro Cuore Don Calabria di Negrar
Phase
Observational
Overall status
Recruiting
Start date
July 10, 2024
Completion date
January 31, 2028
Enrollment
402 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dengue vaccines